Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 3
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus Ł, Ziółkowska B, Kempa-Kamińska N, Ziętek M, Bal W, Kamycka A, Dudzisz-Śledź M, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Czarnecka AM, Rutkowski P. Cybulska-Stopa B, et al. Among authors: piejko k. Melanoma Res. 2023 Jun 1;33(3):208-217. doi: 10.1097/CMR.0000000000000885. Epub 2023 Apr 3. Melanoma Res. 2023. PMID: 37015054
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, Ziętek M, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Rolski J, Sałek-Zań A, Gajewska-Wicher K, Drosik-Kwaśniewska A, Rogala P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: piejko k. Immunotherapy. 2021 Mar;13(4):297-307. doi: 10.2217/imt-2020-0217. Epub 2020 Dec 23. Immunotherapy. 2021. PMID: 33353420
Real-world treatment practice in patients with advanced melanoma.
Cybulska-Stopa B, Piejko K, Pacholczak R, Domagała-Haduch M, Drosik-Kwaśniewska A, Rolski J, Wiktor-Mucha P, Zemełka T. Cybulska-Stopa B, et al. Among authors: piejko k. Contemp Oncol (Pozn). 2020;24(2):118-124. doi: 10.5114/wo.2020.97607. Epub 2020 Jul 3. Contemp Oncol (Pozn). 2020. PMID: 32774137 Free PMC article.
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
Cybulska-Stopa B, Ziętek M, Kamińska-Winciorek G, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Zemełka T, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: piejko k. Melanoma Res. 2021 Feb 1;31(1):49-57. doi: 10.1097/CMR.0000000000000705. Melanoma Res. 2021. PMID: 33165240
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Calik J, Sałek-Zań A, Zemełka T, Bal W, Kamycka A, Świtaj T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. Among authors: piejko k. J Clin Med. 2022 Apr 17;11(8):2239. doi: 10.3390/jcm11082239. J Clin Med. 2022. PMID: 35456332 Free PMC article.
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Seredyńska J, Bal W, Kozak K, Surus-Hyla A, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. Among authors: piejko k. Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123. Cancers (Basel). 2022. PMID: 35565255 Free PMC article.
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa B, Ziętek M, Czarnecka AM, Piejko K, Dziura R, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Seredyńska J, Gądek K, Zemełka T, Teterycz P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: piejko k. J Dermatolog Treat. 2022 Jun;33(4):2168-2174. doi: 10.1080/09546634.2021.1937477. Epub 2021 Jun 14. J Dermatolog Treat. 2022. PMID: 34057374
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
Piejko K, Cybulska-Stopa B, Ziętek M, Dziura R, Galus Ł, Kempa-Kamińska N, Ziółkowska B, Rutkowska E, Kopciński T, Kubiatowski T, Bal W, Suwiński R, Mackiewicz J, Kamińska-Winciorek G, Czarnecka AM, Rutkowski P. Piejko K, et al. Target Oncol. 2023 Mar;18(2):235-245. doi: 10.1007/s11523-023-00954-w. Epub 2023 Mar 11. Target Oncol. 2023. PMID: 36906728 Free PMC article.
Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy.
Cybulska-Stopa B, Ługowska I, Wiśniowski R, Domagała-Haduch M, Rajczykowski M, Piejko K, Bar-Letkiewicz I, Suwiński R, Regulski K, Mackiewicz J. Cybulska-Stopa B, et al. Among authors: piejko k. Contemp Oncol (Pozn). 2020;24(1):34-41. doi: 10.5114/wo.2020.94728. Epub 2020 Mar 30. Contemp Oncol (Pozn). 2020. PMID: 32514236 Free PMC article.